COAPT Trial at 5 Years: Same Doubts Remain About the Efficacy of Transcatheter Edge-to-Edge in Functional Mitral Regurgitation

Overview

Journal Braz J Cardiovasc Surg

Specialty Cardiology & Vascular Diseases

Date 2024 Oct 17

PMID 39418233

Authors

Ovidio A Garcia-Villarreal

Du Chunming

Affiliations

Soon will be listed here.

References

Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G . Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022; 400(10367):1938-1952. DOI: 10.1016/S0140-6736(22)02076-1. View

Serenelli M, Jackson A, Dewan P, Jhund P, Petrie M, Rossignol P . Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2020; 8(3):188-198. PMC: 7086149. DOI: 10.1016/j.jchf.2019.09.011. View

Stone G, Abraham W, Lindenfeld J, Kar S, Grayburn P, Lim D . Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. N Engl J Med. 2023; 388(22):2037-2048. DOI: 10.1056/NEJMoa2300213. View

Cox Z, Zalawadiya S, Simonato M, Redfors B, Zhou Z, Kotinkaduwa L . Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial. JACC Heart Fail. 2023; 11(7):791-805. DOI: 10.1016/j.jchf.2023.03.009. View

Spinka G, Bartko P, Heitzinger G, Prausmuller S, Winter M, Arfsten H . Guideline directed medical therapy and reduction of secondary mitral regurgitation. Eur Heart J Cardiovasc Imaging. 2022; 23(6):755-764. DOI: 10.1093/ehjci/jeac068. View

Komajda M, Anker S, Cowie M, Filippatos G, Mengelle B, Ponikowski P . Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016; 18(5):514-22. DOI: 10.1002/ejhf.510. View

Mullens W, Martens P . Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation. Circulation. 2019; 139(11):1366-1370. DOI: 10.1161/CIRCULATIONAHA.118.038135. View

Greene S, Butler J, Albert N, DeVore A, Sharma P, Duffy C . Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018; 72(4):351-366. DOI: 10.1016/j.jacc.2018.04.070. View

Hagendorff A, Doenst T, Falk V . Echocardiographic assessment of functional mitral regurgitation: opening Pandora's box?. ESC Heart Fail. 2019; 6(4):678-685. PMC: 6676284. DOI: 10.1002/ehf2.12491. View

10.

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

11.

Januzzi J, Omar A, Liu Y, Murphy S, Butler J, Felker G . Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. Circulation. 2022; 146(21):1638-1640. PMC: 9674443. DOI: 10.1161/CIRCULATIONAHA.122.061693. View